A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

Summary

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Chronic Obstructive Pulmonary Disease (COPD)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

40 to 80 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

AstraZeneca

Last updated on ClinicalTrials.gov

September 3, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites